Rekombinanter KRT8 Antikörper

Produktnummer ABIN7126623

Der Kaninchen Monoklonal anti-KRT8 Antikörper wird verwendet zum Nachweis von KRT8 in Proben von Human. Er wurde validiert für WB, IHC, IF und FACS.

Kurzübersicht für Rekombinanter KRT8 Antikörper (ABIN7126623)

Target: KRT8 (Keratin 8 (KRT8))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser KRT8 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS)

Klon: KRT8-4067R

Produktdetails anti-KRT8 Antikörper

Verwendungszweck: Recombinant Cytokeratin 8 (KRT8) Antibody

Spezifität: Epitope of this MAb is located between aa343-357. Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular ( ring-like, perinuclear ) from ductal ( peripheral-predominant ) carcinoma of the breast.

Kreuzreaktivität (Details): Human. Does not react with rat.

Aufreinigung: 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G.

Immunogen: Keratin preparation from a human carcinoma

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise:

Known_Application: Flow Cytometry (1-2 μg/million cells), Immunofluorescence (1-2 μg/mL), Western Blot (2-4 μg/mL), ,Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95 °C followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.

Positive_Control: HCT116, MCF-7, HeLa or A431 cells. Human skin, colon, lung or breast carcinoma.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: Prepared in 10  mM PBS

Konservierungsmittel: Azide free

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Haltbarkeit: 24 months

Details zu KRT8

Target: KRT8 (Keratin 8 (KRT8))

Andere Bezeichnung: KRT8

Hintergrund:

CARD2, CK8, CYK8, CYKER, Cytokeratin Endo A, DreK8, EndoA, K2C8, K8, Keratin 8, Krt 2.8, KRT8, Type-II Keratin Kb8

Colon, HCT-116, HeLa or A431 cells. Human skin, lung or breast carcinoma., MCF-7, Intestine, Stomach.

Molekulargewicht: 52.5kDa

Gen-ID: 3856

UniProt: P05787